康弘药业
(002773)
| 流通市值：211.96亿 | | | 总市值：284.32亿 |
| 流通股本：6.87亿 | | | 总股本：9.21亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,623,865,721.06 | 2,453,661,937.96 | 1,198,743,422.58 | 4,452,657,799 |
| 营业收入 | 3,623,865,721.06 | 2,453,661,937.96 | 1,198,743,422.58 | 4,452,657,799 |
| 二、营业总成本 | 2,438,543,787.09 | 1,619,188,513.48 | 749,205,765.44 | 3,160,129,826.79 |
| 营业成本 | 350,477,855.01 | 246,705,592.31 | 125,209,183.97 | 466,462,782.31 |
| 税金及附加 | 43,239,824.74 | 31,138,857.73 | 13,318,519.54 | 58,965,198.86 |
| 销售费用 | 1,395,399,651.37 | 925,059,691.84 | 423,081,043.08 | 1,646,426,383.28 |
| 管理费用 | 356,795,412.74 | 231,855,999.31 | 108,784,211.05 | 470,904,033.78 |
| 研发费用 | 334,157,560.21 | 214,615,347.81 | 94,301,139.91 | 579,712,150.27 |
| 财务费用 | -41,526,516.98 | -30,186,975.52 | -15,488,332.11 | -62,340,721.71 |
| 其中:利息收入 | 41,612,234.52 | 30,349,352.3 | 15,510,768.84 | 62,906,737.85 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -720,200 | -1,884,200 | -963,000 | -1,056,000 |
| 加:投资收益 | 11,064,472.92 | 8,123,311.62 | -134,361.58 | 47,277,710.26 |
| 资产处置收益 | 8,453.87 | 3,472.82 | 643.36 | 14,202.59 |
| 资产减值损失(新) | -1,217,979.11 | -688,329.89 | 540,911.92 | -2,777,635.36 |
| 信用减值损失(新) | -535,584.73 | -511,588.1 | 10,057.98 | 833,746.07 |
| 其他收益 | 34,172,447.19 | 25,087,140.32 | 16,585,313.78 | 44,509,870.72 |
| 四、营业利润 | 1,228,093,544.11 | 864,603,231.25 | 465,577,222.6 | 1,381,329,866.49 |
| 加:营业外收入 | 2,325,909.72 | 782,347.84 | 428,356.66 | 5,380,741.6 |
| 减:营业外支出 | 21,968,715.88 | 12,923,284.35 | 3,200,443.88 | 34,173,640.96 |
| 五、利润总额 | 1,208,450,737.95 | 852,462,294.74 | 462,805,135.38 | 1,352,536,967.13 |
| 减:所得税费用 | 187,326,343.02 | 130,598,260.91 | 66,180,368.91 | 175,528,898.11 |
| 六、净利润 | 1,021,124,394.93 | 721,864,033.83 | 396,624,766.47 | 1,177,008,069.02 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,021,124,394.93 | 721,864,033.83 | 396,624,766.47 | 1,177,008,069.02 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,032,906,564.53 | 729,699,133.47 | 400,017,678.69 | 1,191,230,760.93 |
| 少数股东损益 | -11,782,169.6 | -7,835,099.64 | -3,392,912.22 | -14,222,691.91 |
| 扣除非经常损益后的净利润 | 1,023,661,750.61 | 722,555,631.64 | 390,453,690.27 | 1,183,679,032.35 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.12 | 0.79 | 0.43 | 1.3 |
| (二)稀释每股收益 | 1.12 | 0.79 | 0.43 | 1.3 |
| 八、其他综合收益 | -322,319.27 | -64,852.09 | -518,692.27 | 13,717.61 |
| 归属于母公司股东的其他综合收益 | -322,319.27 | -64,852.09 | -518,692.27 | 13,717.61 |
| 九、综合收益总额 | 1,020,802,075.66 | 721,799,181.74 | 396,106,074.2 | 1,177,021,786.63 |
| 归属于母公司股东的综合收益总额 | 1,032,584,245.26 | 729,634,281.38 | 399,498,986.42 | 1,191,244,478.54 |
| 归属于少数股东的综合收益总额 | -11,782,169.6 | -7,835,099.64 | -3,392,912.22 | -14,222,691.91 |
| 公告日期 | 2025-10-29 | 2025-08-28 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |